Quality markers for cosmetic peptides — purity, copper-complex stability, and topical formulation tests

Cosmetic peptide quality verification has its own specific considerations. The GHK-Cu copper-complex is harder to characterize than a standard peptide because the bioactive species is the metal complex rather than the peptide alone. Topical formulations have additional quality considerations that pure injectable peptides do not. And the melanotan and PT-141 family have their own substitution patterns. This thread covers what to look for on a COA across the different compound families in this category.

The basics still apply.
The general COA-reading skills covered in the COA & Lab Results category apply here. HPLC purity, mass spectrometry confirmation of identity, named accredited third-party lab, specific batch number matching the vial. If those basics are not present, do not buy regardless of the category. This thread covers the additional considerations specific to cosmetic peptides.

GHK and GHK-Cu specifically.

The complex versus the free peptide. The bioactive species is GHK-Cu, the copper-bound complex. Some vendors sell uncomplexed GHK (the tripeptide alone) and customer-add the copper at reconstitution time. Other vendors sell pre-formed GHK-Cu complex. Both can be legitimate but the documentation requirements differ. Pre-formed GHK-Cu complex should have copper content reported on the COA — typically expressed as percentage by weight or as a copper:peptide molar ratio. Uncomplexed GHK should have purity reported but does not have a copper-complex assay because the complex is formed at reconstitution.

Mass spec expectations. Free GHK has a theoretical molecular weight of 340.38 Da. The GHK-Cu complex has approximately 403.93 Da depending on the specific copper coordination geometry. The mass spec value on the COA should match the form being sold. Vendors selling "GHK-Cu" with a mass spec showing only 340 Da are selling uncomplexed GHK and should disclose that.

Copper purity and source. The copper used in pre-complexed GHK-Cu should be of analytical grade. Lower-grade copper sources can contain trace contaminants (lead, arsenic, other heavy metals) that should not be present in a research peptide product. Higher-quality vendors test for and report heavy metal content.

Stability. The GHK-Cu complex is more stable than free GHK + free copper, but stability still varies with formulation. Aqueous solutions of GHK-Cu can degrade through several pathways including copper-mediated peptide oxidation. Lyophilized GHK-Cu is more stable than aqueous formulations. Vendors making extended stability claims should provide supporting data.

Topical formulation quality (if applicable).
For topical GHK-Cu products (creams, serums, etc.), additional quality considerations apply beyond what a pure peptide COA would cover.

• Concentration of active GHK-Cu in the formulation should be specifically stated, not "contains GHK-Cu" without quantitative content.
• Carrier formulation stability affects how long the active stays bioactive in the bottle. Some carrier ingredients are incompatible with copper peptides and can cause degradation or precipitation.
• Preservative system is required for any aqueous topical formulation that will be used over weeks. The preservatives should not interfere with the active.
• pH range matters for stability and skin tolerance. GHK-Cu is most stable in mildly acidic to neutral pH ranges.

Vendors selling topical GHK-Cu products without specifying active concentration are providing inadequate documentation. "Contains GHK-Cu" is marketing copy, not a quality specification.

Melanotan I and II.

Mass spec expectations. Melanotan I (afamelanotide) has a theoretical molecular weight of 1646.85 Da. Melanotan II has a theoretical molecular weight of 1024.18 Da. The molecular weight difference is large and unambiguous on mass spec.

Acetate content. Both melanotan compounds are typically synthesized as acetate salts via SPPS. The acetate content (typically 5-15% by mass) should be reported or the net peptide content should be given directly. As with other peptides in this category, the labeled mass without acetate disclosure is technically accurate but provides less useful documentation for accurate dose calculation.

The melanotan I versus melanotan II clarity. Vendors must clearly disclose which melanotan is in the vial. The two compounds have different receptor selectivity profiles (melanotan I more selective for MC1R, melanotan II non-selective across MC1R/MC3R/MC4R/MC5R) which produces different effect and side effect profiles. A vendor selling "melanotan" without specifying I or II is providing dangerously ambiguous documentation.

PT-141 (bremelanotide).

Mass spec expectations. PT-141 has a theoretical molecular weight of 1025.18 Da. Note this is very close to melanotan II (1024.18 Da) — the two compounds differ by approximately 1 Da, reflecting that PT-141 has a C-terminal carboxylic acid where melanotan II has a C-terminal amide. Mass spec resolution sufficient to distinguish a 1 Da difference is not always present in lower-end labs. The compounds have different receptor selectivity (PT-141 is more selective for MC4R) and different research applications. High-precision mass spec or sequence-confirming analysis should be available from any quality vendor.

Hair-loss peptides (PTD-DBM and related).

The published research base on these compounds is younger and the quality landscape is less mature. COAs from vendors selling these compounds vary widely in completeness. Look for the basics (HPLC purity, mass spec confirmation, named third-party lab) and treat any vendor providing less than that as higher risk.

What a strong cosmetic peptide COA looks like in practice.

For pre-complexed GHK-Cu: HPLC purity above 97%. Mass spec confirming the GHK-Cu complex molecular weight (around 403.93 Da). Copper content reported and matching expected stoichiometry. Heavy metals testing showing absence of contaminants. Named accredited third-party lab.

For uncomplexed GHK: HPLC purity above 97%. Mass spec confirming free GHK (340.38 Da). Acetate content or net peptide content reported.

For melanotan I or II: HPLC purity above 97%. Mass spec confirming the specific compound's molecular weight. Acetate content or net peptide content reported. Compound name explicit (I or II, not just "melanotan").

For PT-141: HPLC purity above 97%. High-precision mass spec confirming PT-141 (1025.18 Da) and not melanotan II (1024.18 Da).

For topical formulations: Active concentration specified. Carrier ingredients listed. Preservative system disclosed. pH within stable range.

If you are evaluating a vendor for any compound in this category, request the COA before ordering and verify the specific quality markers that apply to that compound family. Post questions or specific COAs in the Quality and COA discussion threads if you want a second pair of eyes.